Atlas Trials

Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer

Clinical trial NCT00380835 · WITHDRAWN

Trial details

NCT number
NCT00380835
Sponsor
Celgene Corporation
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Enrollment
66

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.